sur Relief Therapeutics Holding SA (isin : CH1251125998)
European Patent Office Grants Relief Therapeutics Patent for RLF-TD011
Relief Therapeutics Holding SA announced that the European Patent Office has decided to grant a patent for RLF-TD011. This patent is crucial for protecting RLF-TD011, used in the treatment of wounds caused by epidermolysis bullosa (EB), across key European regions. The patent, set to be issued on February 26, 2025, will remain valid until 2040. Applications for corresponding patents are under review in other markets, including the United States and China.
RLF-TD011, which has orphan drug designation from the U.S. FDA, is part of Relief's strategic development plan. The company aims for further designations to secure market exclusivity. In recent trials, RLF-TD011 demonstrated positive outcomes for EB treatment. Relief is currently preparing a pre-IND meeting package for submission to the FDA to outline its future clinical and regulatory path.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Relief Therapeutics Holding SA